Presentation is loading. Please wait.

Presentation is loading. Please wait.

Therapeutic validation in orthotopic lung PDX. (A).

Published byCalvin Banks Modified over 5 years ago

Similar presentations

Presentation on theme: "Therapeutic validation in orthotopic lung PDX. (A)."— Presentation transcript:

1 Therapeutic validation in orthotopic lung PDX. (A).
Therapeutic validation in orthotopic lung PDX. (A). Biopsies from patients carrying KRAS-mutant;TP53-deficient lung adenocarcinomas were orthotopically implanted in Crl:NU-Foxn1nu mice and subjected to treatment with either vehicle, cisplatin/paclitaxel chemotherapy or dasatinib/demcizumab. Positron emission tomography (PET) follow-up demonstrated a better response when compared with chemotherapy. CD31 immunostaining showed a substantial decrease of the endothelial compartment in tumours subjected to the combined therapy. (B). Percentages of alteration frequencies identified in different NSCLC studies obtained from the TCGA database ( Red=gene amplification; green=mutation. PDX, patient-derived xenograft; NSCLC, non-small cell lung carcinoma. Chiara Ambrogio et al. ESMO Open 2016;1:e000076 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Therapeutic validation in orthotopic lung PDX. (A)."

Similar presentations

Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.

Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.

Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Similar presentations

Ads by Google